Beneficial Effects of PIN1 Inhibition on Diabetes Mellitus: A Concise Review.
Meeramol C ChellappanV SoumyaShriraam MahadevanM K KathiravanJ SaravananSoniya PhadtePublished in: Endocrine, metabolic & immune disorders drug targets (2024)
Type 2 diabetes mellitus is a long-term medical illness in which the body either becomes resistant to insulin or fails to produce it sufficiently. Mostly, combinatorial therapy is required to control blood glucose levels. However, combinatorial therapy has detrimental side effects. The prevalence of the cases and subsequent increases in medical costs of the same intimidate human health globally. While there have been a lot of studies focused on developing diabetic regimens that work to lower blood glucose levels, their effectiveness is short-lived because of unfavorable side effects, such as weight gain and hypoglycemia. In recent years, the PIN1 (protein interacting with NIMA) enzyme has attracted the attention of researchers. Previous studies suggested that PIN1 may act on the various substrates that are involved in the progression of T2DM and also help in the management of diabetes-related disorders. Thus, the focus of the current review is to examine the correlation between PIN1, T2DM and its related disorders and explore the possibility of developing novel therapeutic targets through PIN1 inhibition.
Keyphrases
- glycemic control
- blood glucose
- type diabetes
- weight gain
- human health
- weight loss
- risk assessment
- healthcare
- insulin resistance
- body mass index
- randomized controlled trial
- birth weight
- case control
- cardiovascular disease
- risk factors
- systematic review
- working memory
- stem cells
- mesenchymal stem cells
- physical activity
- protein protein
- metabolic syndrome
- skeletal muscle
- cardiovascular risk factors
- smoking cessation
- protein kinase